Building upon this, SH3BP5-mediated modulation of the TME extends to the regulation of immune checkpoints—which are components of the immune system that cancer cells exploit to evade immune clearance and are key determinants of immune evasion and therapeutic response [38]—suggesting that alterations in the TME may enhance the efficacy of immune checkpoint inhibitors [39]. The gene discussed is SH3BP5; the disease is cancer.